The Grid’s Biggest Problem Isn’t Making Power. It’s Getting It to the Right Place at the Right Time

The global battery energy storage market is projected to grow from $50.81B in 2025 to $105.96B by 2030, driven by renewable integration and grid modernization. NOMAD Power Solutions (NMAD) advanced its Vermont project to Phase 3, deploying transportable BESS units with DOE support. The $19M project includes $9.5M in DOE funding and aims to enhance grid flexibility.

The US administration, according to a President Trump roundtable reported by Energy Metal News, committed over $2 billion to domestic battery and critical-mineral projects. The largest item is a $1.4 billion Defense Department loan to Sila Nanotechnologies, plus $400 million to Sunrise Energy Metals, $150 million to Niron Magnetics, and an $85.5 million equity investment in Strategic Bauxite. The article also highlights related company updates including NOMAD Power Solutions (NMAD).

A commentary issued for NOMAD Power Solutions (NMAD) says AI data centers are straining U.S. grid capacity and that long interconnection and permitting delays are driving demand for behind-the-meter power. It highlights NMAD’s Voyager battery trailer upgrades (Eagle 1.3 to 2.025 MWh, Falcon 664 kWh to 1.0 MWh) and compares peers Fluence (FLNC), Bloom Energy (BE), and Vertiv (VRT).

Chevron will sell its stake in Hess Midstream and DJ Basin assets for $200M, reducing Bakken midstream costs by 50% and boosting returns. The deal, expected to close by late 2026, will also remove $3.7B in debt from Chevron's balance sheet but result in a $3B-$4B after-tax loss. Chevron acquired Hess Corporation in July 2025.

WhiteHawk Minerals launched a Series F Preferred Stock offering, aiming to raise up to $100 million. The company hired Preferred Capital Securities as dealer manager and Preferred Shareholder Services for investor support. The offering consists of up to 100,000 shares at $1,000 each, with a 7.5% annual dividend. The moves are part of efforts to streamline capital raising and operations.

Rocket Pharmaceuticals secured a $150 million term loan from Hercules Capital, with a $35 million initial draw. The loan has a 2030 maturity, extendable to 2031, and includes interest-only periods tied to milestones. The company also issued warrants for up to 1.76 million shares at $2.99 to lenders. The funding aims to support its pipeline, including RP-A501 for Danon Disease, and operations.